AFA
JAZZ icon

Abacus FCF Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Abacus FCF Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,254
Closed -$523K – 155
2023
Q4 		$523K Buy
+4,254
New +$531K 0.15% 141
2021
Q3 		– Sell
-4,401
Closed -$796K – 144
2021
Q2 		$796K Sell
4,401
-319
-7% -$55.3K 0.41% 121
2021
Q1 		$794K Buy
+4,720
New +$777K 0.4% 102
2016
Q3 		– Sell
-10,391
Closed -$1.47M – 112
2016
Q2 		$1.47M Buy
+10,391
New +$1.53M 0.95% 66

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Abacus FCF Advisors's JAZZ Position: Q1 2024 in Review

Abacus FCF Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2024, closing a stake of 4,254 shares — an estimated $523K sold.

Abacus FCF Advisors first reported a position in JAZZ in Q2 2016 and held it in 4 quarters. The position peaked at $1.47M in Q2 2016. 480 funds tracked by Wall St. Rank hold JAZZ as of Q1 2024.

  • Abacus FCF Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Abacus FCF Advisors sold 4,254 Jazz Pharmaceuticals shares in Q1 2024, an estimated $523K.
  • Abacus FCF Advisors first reported a position in Jazz Pharmaceuticals in Q2 2016 and held it in 4 quarters.
  • Abacus FCF Advisors's Jazz Pharmaceuticals position peaked at $1.47M in Q2 2016.
  • 480 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2024.

Based on Abacus FCF Advisors's 13F filing for Q1 2024, filed 12 Apr 2024.